0000899243-20-034109.txt : 20201216 0000899243-20-034109.hdr.sgml : 20201216 20201216161527 ACCESSION NUMBER: 0000899243-20-034109 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201215 FILED AS OF DATE: 20201216 DATE AS OF CHANGE: 20201216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rolfe Lindsey CENTRAL INDEX KEY: 0001650504 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 201392595 MAIL ADDRESS: STREET 1: C/O CLOVIS ONCOLOGY, INC. STREET 2: 499 ILLINOIS STREET, SUITE 200 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 5500 FLATIRON PARKWAY STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-15 0 0001466301 Clovis Oncology, Inc. CLVS 0001650504 Rolfe Lindsey C/O CLOVIS ONCOLOGY, INC. 5500 FLATIRON PARKWAY, SUITE 100 BOULDER CO 80301 0 1 0 0 See Remarks Common Stock 2020-12-15 4 M 0 17241 3.28 A 70718 D Common Stock 2020-12-15 4 F 0 14153 5.11 D 56565 D Employee Stock Option (right to buy) 3.28 2020-12-15 4 M 0 17241 0.00 D 2021-03-01 Common Stock 17241 0 D The option vested as to 25% of the shares on March 1, 2012, and the remainder vested in substantially equal installments over the 36 months immediately following such date. Chief Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance /s/ Lindsey Rolfe 2020-12-16